Abatacept
The risk or severity of adverse effects can be increased when Abatacept is combined with Natalizumab.
Abetimus
The risk or severity of adverse effects can be increased when Abetimus is combined with Natalizumab.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Natalizumab.
Advertisement
Adefovir
The risk or severity of adverse effects can be increased when Adefovir is combined with Natalizumab.
Ado-Trastuzumab Emtansine
The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Natalizumab.
Alefacept
The risk or severity of adverse effects can be increased when Alefacept is combined with Natalizumab.
Advertisement
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Natalizumab.
Altretamine
The risk or severity of adverse effects can be increased when Altretamine is combined with Natalizumab.
Amsacrine
The risk or severity of adverse effects can be increased when Amsacrine is combined with Natalizumab.
Advertisement
Anakinra
The risk or severity of adverse effects can be increased when Anakinra is combined with Natalizumab.
Anhydrous Tacrolimus
The risk or severity of adverse effects can be increased when Tacrolimus is combined with Natalizumab.
Anthrax immune globulin, human
The risk or severity of adverse effects can be increased when Natalizumab is combined with Anthrax immune globulin human.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Natalizumab.
Azacitidine
The risk or severity of adverse effects can be increased when Azacitidine is combined with Natalizumab.
Azathioprine
The risk or severity of adverse effects can be increased when Azathioprine is combined with Natalizumab.
Basiliximab
The risk or severity of adverse effects can be increased when Basiliximab is combined with Natalizumab.
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Natalizumab.
BCG, Live, Connaught Strain
The risk or severity of adverse effects can be increased when Natalizumab is combined with Bacillus calmette-guerin substrain connaught live antigen.
BCG, Live, Tice Strain
The risk or severity of adverse effects can be increased when Natalizumab is combined with Bacillus calmette-guerin substrain tice live antigen.
Belatacept
The risk or severity of adverse effects can be increased when Belatacept is combined with Natalizumab.
Belimumab
The risk or severity of adverse effects can be increased when Belimumab is combined with Natalizumab.
Benznidazole
The risk or severity of adverse effects can be increased when Benznidazole is combined with Natalizumab.
Betamethasone
The risk or severity of adverse effects can be increased when Betamethasone is combined with Natalizumab.
Bleomycin
The risk or severity of adverse effects can be increased when Bleomycin is combined with Natalizumab.
Blinatumomab
The risk or severity of adverse effects can be increased when Blinatumomab is combined with Natalizumab.
Brentuximab Vedotin
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Natalizumab.
Brodalumab
The risk or severity of adverse effects can be increased when Brodalumab is combined with Natalizumab.
Budesonide
The risk or severity of adverse effects can be increased when Budesonide is combined with Natalizumab.
Busulfan
The risk or severity of adverse effects can be increased when Busulfan is combined with Natalizumab.
C1 esterase inhibitor (human)
The risk or severity of adverse effects can be increased when Human C1-esterase inhibitor is combined with Natalizumab.
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Natalizumab.
Canakinumab
The risk or severity of adverse effects can be increased when Canakinumab is combined with Natalizumab.
Capecitabine
The risk or severity of adverse effects can be increased when Capecitabine is combined with Natalizumab.
Carboplatin
The risk or severity of adverse effects can be increased when Carboplatin is combined with Natalizumab.
Carmustine
The risk or severity of adverse effects can be increased when Carmustine is combined with Natalizumab.
Certolizumab Pegol
The risk or severity of adverse effects can be increased when Certolizumab pegol is combined with Natalizumab.
Chlorambucil
The risk or severity of adverse effects can be increased when Chlorambucil is combined with Natalizumab.
Cisplatin
The risk or severity of adverse effects can be increased when Cisplatin is combined with Natalizumab.
Cladribine
The risk or severity of adverse effects can be increased when Cladribine is combined with Natalizumab.
Clofarabine
The risk or severity of adverse effects can be increased when Clofarabine is combined with Natalizumab.
Corticotropin
The risk or severity of adverse effects can be increased when Corticotropin is combined with Natalizumab.
Cortisone Acetate
The risk or severity of adverse effects can be increased when Cortisone acetate is combined with Natalizumab.
Cyclophosphamide
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Natalizumab.
Cyclophosphamide Anhydrous
The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Natalizumab.
Cyclosporine
The risk or severity of adverse effects can be increased when Cyclosporine is combined with Natalizumab.
Cytarabine
The risk or severity of adverse effects can be increased when Cytarabine is combined with Natalizumab.
Dacarbazine
The risk or severity of adverse effects can be increased when Dacarbazine is combined with Natalizumab.
Daclizumab
The risk or severity of adverse effects can be increased when Daclizumab is combined with Natalizumab.
Dactinomycin
The risk or severity of adverse effects can be increased when Dactinomycin is combined with Natalizumab.
Dasatinib
The risk or severity of adverse effects can be increased when Dasatinib is combined with Natalizumab.
Dasatinib Anhydrous
The risk or severity of adverse effects can be increased when Dasatinib is combined with Natalizumab.
Daunorubicin
The risk or severity of adverse effects can be increased when Daunorubicin is combined with Natalizumab.
Deflazacort
The risk or severity of adverse effects can be increased when Deflazacort is combined with Natalizumab.
Denosumab
The risk or severity of adverse effects can be increased when Denosumab is combined with Natalizumab.
Dexamethasone
The risk or severity of adverse effects can be increased when Dexamethasone is combined with Natalizumab.
Dimethyl Fumarate
The risk or severity of adverse effects can be increased when Dimethyl fumarate is combined with Natalizumab.
Dinutuximab
The risk or severity of adverse effects can be increased when Dinutuximab is combined with Natalizumab.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Natalizumab.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Natalizumab.
Doxorubicin
The risk or severity of adverse effects can be increased when Doxorubicin is combined with Natalizumab.
Doxorubicin Hydrochloride
The risk or severity of adverse effects can be increased when Doxorubicin is combined with Natalizumab.
Eculizumab
The risk or severity of adverse effects can be increased when Eculizumab is combined with Natalizumab.
Efalizumab
The risk or severity of adverse effects can be increased when Efalizumab is combined with Natalizumab.
Epirubicin
The risk or severity of adverse effects can be increased when Epirubicin is combined with Natalizumab.
Estramustine
The risk or severity of adverse effects can be increased when Estramustine is combined with Natalizumab.
Etanercept
The risk or severity of adverse effects can be increased when Etanercept is combined with Natalizumab.
Etoposide
The risk or severity of adverse effects can be increased when Etoposide is combined with Natalizumab.
Everolimus
The risk or severity of adverse effects can be increased when Everolimus is combined with Natalizumab.
Fingolimod
The risk or severity of adverse effects can be increased when Fingolimod is combined with Natalizumab.
Floxuridine
The risk or severity of adverse effects can be increased when Floxuridine is combined with Natalizumab.
Fludarabine
The risk or severity of adverse effects can be increased when Fludarabine is combined with Natalizumab.
Fludrocortisone
The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Natalizumab.
Fluorouracil
The risk or severity of adverse effects can be increased when Fluorouracil is combined with Natalizumab.
Gallium Nitrate
The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Natalizumab.
Gemcitabine
The risk or severity of adverse effects can be increased when Gemcitabine is combined with Natalizumab.
Gemtuzumab ozogamicin
The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Natalizumab.
Glatiramer
The risk or severity of adverse effects can be increased when Glatiramer Acetate is combined with Natalizumab.
Glimepiride
The risk or severity of adverse effects can be increased when Glimepiride is combined with Natalizumab.
Golimumab
The risk or severity of adverse effects can be increased when Golimumab is combined with Natalizumab.
Hepatitis A Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Natalizumab is combined with Hepatitis A Vaccine.
Hepatitis B Surface Antigen Vaccine
The risk or severity of adverse effects can be increased when Natalizumab is combined with Hepatitis B Vaccine (Recombinant).
Hydrocortisone
The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Natalizumab.
Hydroxyurea
The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Natalizumab.
Hypericin
The risk or severity of adverse effects can be increased when Hypericin is combined with Natalizumab.
Ibritumomab Tiuxetan
The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Natalizumab.
Ibrutinib
The risk or severity of adverse effects can be increased when Ibrutinib is combined with Natalizumab.
Icatibant
The risk or severity of adverse effects can be increased when Icatibant is combined with Natalizumab.
Idarubicin
The risk or severity of adverse effects can be increased when Idarubicin is combined with Natalizumab.
Idelalisib
The risk or severity of adverse effects can be increased when Idelalisib is combined with Natalizumab.
Ifosfamide
The risk or severity of adverse effects can be increased when Ifosfamide is combined with Natalizumab.
Imatinib
The risk or severity of adverse effects can be increased when Imatinib is combined with Natalizumab.
Imiquimod
The risk or severity of adverse effects can be increased when Imiquimod is combined with Natalizumab.
Infliximab
The risk or severity of adverse effects can be increased when Infliximab is combined with Natalizumab.
Infliximab-Abda
The risk or severity of adverse effects can be increased when Infliximab is combined with Natalizumab.
Infliximab-Dyyb
The risk or severity of adverse effects can be increased when Infliximab is combined with Natalizumab.
Irinotecan
The risk or severity of adverse effects can be increased when Irinotecan is combined with Natalizumab.
Leflunomide
The risk or severity of adverse effects can be increased when Leflunomide is combined with Natalizumab.
Lenalidomide
The risk or severity of adverse effects can be increased when Lenalidomide is combined with Natalizumab.
Lomustine
The risk or severity of adverse effects can be increased when Lomustine is combined with Natalizumab.
Mechlorethamine
The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Natalizumab.
Melphalan
The risk or severity of adverse effects can be increased when Melphalan is combined with Natalizumab.
Mepolizumab
The risk or severity of adverse effects can be increased when Mepolizumab is combined with Natalizumab.
Mercaptopurine
The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Natalizumab.
MERCAPTOPURINE ANHYDROUS
The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Natalizumab.
Methotrexate
The risk or severity of adverse effects can be increased when Methotrexate is combined with Natalizumab.
Methylprednisolone
The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Natalizumab.
Mitomycin
The risk or severity of adverse effects can be increased when Mitomycin is combined with Natalizumab.
Mitoxantrone
The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Natalizumab.
Muromonab-CD3
The risk or severity of adverse effects can be increased when Muromonab is combined with Natalizumab.
MYCOPHENOLATE
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Natalizumab.
Mycophenolate Mofetil
The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Natalizumab.
Mycophenolic Acid
The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Natalizumab.
Nelarabine
The risk or severity of adverse effects can be increased when Nelarabine is combined with Natalizumab.
Nilotinib
The risk or severity of adverse effects can be increased when Nilotinib is combined with Natalizumab.
Obinutuzumab
The risk or severity of adverse effects can be increased when Obinutuzumab is combined with Natalizumab.
Ocrelizumab
Ocrelizumab may increase the immunosuppressive activities of Natalizumab.
Oxaliplatin
The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Natalizumab.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Natalizumab.
Palbociclib
The risk or severity of adverse effects can be increased when Palbociclib is combined with Natalizumab.
Panobinostat
The risk or severity of adverse effects can be increased when Panobinostat is combined with Natalizumab.
Pazopanib
The risk or severity of adverse effects can be increased when Pazopanib is combined with Natalizumab.
Pegaspargase
The risk or severity of adverse effects can be increased when Pegaspargase is combined with Natalizumab.
Pemetrexed
The risk or severity of adverse effects can be increased when Pemetrexed is combined with Natalizumab.
Pentostatin
The risk or severity of adverse effects can be increased when Pentostatin is combined with Natalizumab.
Phenylalanine
The risk or severity of adverse effects can be increased when L-Phenylalanine is combined with Natalizumab.
Pimecrolimus
The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Natalizumab.
Pirarubicin
The risk or severity of adverse effects can be increased when Pirarubicin is combined with Natalizumab.
Pirfenidone
The risk or severity of adverse effects can be increased when Pirfenidone is combined with Natalizumab.
Pomalidomide
The risk or severity of adverse effects can be increased when Pomalidomide is combined with Natalizumab.
Pralatrexate
The risk or severity of adverse effects can be increased when Pralatrexate is combined with Natalizumab.
Prednisolone
The risk or severity of adverse effects can be increased when Prednisolone is combined with Natalizumab.
Prednisone
The risk or severity of adverse effects can be increased when Prednisone is combined with Natalizumab.
Procarbazine
The risk or severity of adverse effects can be increased when Procarbazine is combined with Natalizumab.
Rabbit anti-human T-lymphocyte globulin
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Natalizumab.
Rabies Immune Globulin, Human
The risk or severity of adverse effects can be increased when Natalizumab is combined with Human rabies virus immune globulin.
Rabies Virus Vaccine Flury-Lep Strain
The risk or severity of adverse effects can be increased when Natalizumab is combined with Rabies virus inactivated antigen, A.
Rilonacept
The risk or severity of adverse effects can be increased when Rilonacept is combined with Natalizumab.
Rituximab
The risk or severity of adverse effects can be increased when Rituximab is combined with Natalizumab.
Roflumilast
Roflumilast may increase the immunosuppressive activities of Natalizumab.
ROTAVIRUS VACCINE, LIVE
The risk or severity of adverse effects can be increased when Natalizumab is combined with Rotavirus Vaccine.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The risk or severity of adverse effects can be increased when Natalizumab is combined with Rubella virus vaccine.
Ruxolitinib
The risk or severity of adverse effects can be increased when Ruxolitinib is combined with Natalizumab.
Salmonella enterica subsp. enterica serovar typhi
The risk or severity of adverse effects can be increased when Natalizumab is combined with Salmonella typhi ty21a live antigen.
Secukinumab
The risk or severity of adverse effects can be increased when Secukinumab is combined with Natalizumab.
Siltuximab
The risk or severity of adverse effects can be increased when Siltuximab is combined with Natalizumab.
sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Natalizumab.
Sirolimus
The risk or severity of adverse effects can be increased when Sirolimus is combined with Natalizumab.
Sorafenib
The risk or severity of adverse effects can be increased when Sorafenib is combined with Natalizumab.
Streptozocin
The risk or severity of adverse effects can be increased when Streptozocin is combined with Natalizumab.
Sunitinib
The risk or severity of adverse effects can be increased when Sunitinib is combined with Natalizumab.
Tacrolimus
The risk or severity of adverse effects can be increased when Tacrolimus is combined with Natalizumab.
Temozolomide
The risk or severity of adverse effects can be increased when Temozolomide is combined with Natalizumab.
Temsirolimus
The risk or severity of adverse effects can be increased when Temsirolimus is combined with Natalizumab.
Teniposide
The risk or severity of adverse effects can be increased when Teniposide is combined with Natalizumab.
Teriflunomide
The risk or severity of adverse effects can be increased when Teriflunomide is combined with Natalizumab.
Tetanus Toxoid Vaccine, Inactivated
The risk or severity of adverse effects can be increased when Natalizumab is combined with Clostridium tetani toxoid antigen (formaldehyde inactivated).
Thalidomide
The risk or severity of adverse effects can be increased when Thalidomide is combined with Natalizumab.
Thioguanine
The risk or severity of adverse effects can be increased when Tioguanine is combined with Natalizumab.
Thioguanine Anhydrous
The risk or severity of adverse effects can be increased when Tioguanine is combined with Natalizumab.
Thiotepa
The risk or severity of adverse effects can be increased when Thiotepa is combined with Natalizumab.
Thymocyte Immunoglobulin, Equine
The risk or severity of adverse effects can be increased when Antilymphocyte immunoglobulin (horse) is combined with Natalizumab.
Tocilizumab
The risk or severity of adverse effects can be increased when Tocilizumab is combined with Natalizumab.
Tofacitinib
The risk or severity of adverse effects can be increased when Tofacitinib is combined with Natalizumab.
Topotecan
The risk or severity of adverse effects can be increased when Topotecan is combined with Natalizumab.
Tositumomab
The risk or severity of adverse effects can be increased when Tositumomab is combined with Natalizumab.
Trabectedin
The risk or severity of adverse effects can be increased when Trabectedin is combined with Natalizumab.
Trastuzumab
Trastuzumab may increase the neutropenic activities of Natalizumab.
Tretinoin
The risk or severity of adverse effects can be increased when Tretinoin is combined with Natalizumab.
Triamcinolone
The risk or severity of adverse effects can be increased when Triamcinolone is combined with Natalizumab.
Trofosfamide
The risk or severity of adverse effects can be increased when Trofosfamide is combined with Natalizumab.
Typhoid Vaccine Live Ty21a
The risk or severity of adverse effects can be increased when Natalizumab is combined with Salmonella typhi ty21a live antigen.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The risk or severity of adverse effects can be increased when Natalizumab is combined with Salmonella typhi ty2 vi polysaccharide antigen.
Ustekinumab
The risk or severity of adverse effects can be increased when Ustekinumab is combined with Natalizumab.
Varicella Virus Vaccine Live (Oka-Merck) strain
The risk or severity of adverse effects can be increased when Natalizumab is combined with Varicella Zoster Vaccine (Live/Attenuated).
Vedolizumab
The risk or severity of adverse effects can be increased when Vedolizumab is combined with Natalizumab.
Vilanterol
The risk or severity of adverse effects can be increased when Vilanterol is combined with Natalizumab.
Vinblastine
The risk or severity of adverse effects can be increased when Vinblastine is combined with Natalizumab.
Vincristine
The risk or severity of adverse effects can be increased when Vincristine is combined with Natalizumab.
Vindesine
The risk or severity of adverse effects can be increased when Vindesine is combined with Natalizumab.
Vinorelbine
The risk or severity of adverse effects can be increased when Vinorelbine is combined with Natalizumab.
Yellow Fever Vaccine
The risk or severity of adverse effects can be increased when Natalizumab is combined with Yellow Fever Vaccine.
Yellow-Fever Virus Vaccine, 17D-204 strain
The risk or severity of adverse effects can be increased when Natalizumab is combined with Yellow Fever Vaccine.
